CIBG 166a

Drug Profile

CIBG 166a

Alternative Names: CIGB-166a

Latest Information Update: 31 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Class Recombinant proteins
  • Mechanism of Action Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer; Wet age-related macular degeneration

Most Recent Events

  • 31 Dec 2015 CIBG 166a is available for licensing as of 31 Dec 2015. http://gndp.cigb.edu.cu
  • 31 Dec 2015 Center for Genetic Engineering and Biotechnology has patent protection for CIGB 166a in Cuba
  • 31 Dec 2015 Early research in Cancer in Cuba (unspecified route), before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top